Ding Y-J, Han B, Yang B, Zhu M
Provincial Hospital Affiliated to Shandong University, Jinan, PR China.
Eur Rev Med Pharmacol Sci. 2014;18(18):2596-8.
The aim of this study was to clarify the role of N-terminal pro-brain natriuretic peptide, (NT-proBNP) in ibuprofen on preterm infants with patent ductus arteriosus (PDA).
Preterm infants with PDA were enrolled in the present study. Patients were randomized into two groups: ibuprofen group received oral ibuprofen 10 mg/kg, followed by 5 mg/kg after 24 and 48 h, and the placebo group received the same volume of 5% glucose. PDA and NT-proBNP were detected during 24 hours, 3 and 7 days of age.
The results indicated that babies who received oral ibuprofen had higher PDA closure at 7 days after treatment (p < 0.05). Significantly decrease of NT-proBNP was found in ibuprofen group than the placebo group at 3 and 7 days (all p < 0.05).
Collectively, the favorable effects of ibuprofen on PDA in premature infants maybe mediated in part by the reduction of NT-proBNP level.
本研究旨在阐明N端前脑钠肽(NT-proBNP)在布洛芬对动脉导管未闭(PDA)早产儿治疗中的作用。
将患有PDA的早产儿纳入本研究。患者被随机分为两组:布洛芬组口服布洛芬10mg/kg,24小时和48小时后再给予5mg/kg,安慰剂组给予相同体积的5%葡萄糖。在出生后24小时、3天和7天时检测PDA和NT-proBNP。
结果表明,接受口服布洛芬治疗的婴儿在治疗7天后动脉导管未闭闭合率更高(p<0.05)。布洛芬组在3天和7天时NT-proBNP水平显著低于安慰剂组(均p<0.05)。
总体而言,布洛芬对早产儿PDA的有益作用可能部分是通过降低NT-proBNP水平介导的。